The Pharmacotherapies for Alcohol and Substance Abuse (PASA) consortium is funded by the Alcohol and Substance Abuse Disorders Research Program.  The goal of the PASA consortium is to fund study applications for developing new medications that can be brought to therapeutic use to improve treatment outcomes for alcohol and substance use disorders (ASUD), especially as related to post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI). The two upcoming research funding opportunities are focused on:

1.Request for Application (RFA) #4a: Small-cost and short-duration planning grant awarded to investigators concerning a specific compound or combination of compounds. Designed to determine the clinical development plan (CDP) and associated studies needed to advance the compound to FDA approval for ASUD treatment.

2.Request for Application (RFA) #4b: Full study implementation awards for proof-of-principle basic research to determine which compounds are most appropriate for human research trials.

The RFAs are available from the PASA Consortium website at: